Hydrogel for repairing pigment-free scars of diabetic wound surfaces as well as preparation method and application of hydrogel
Through dynamic borate bond hydrogels, they release drugs in an acidic and high-sugar environment, regulate inflammatory responses, inhibit scar formation of diabetic wounds, solve the difficulty of healing and scar problems of diabetic wounds, and achieve rapid and pigment-free healing.
Patent Information
- Application Number
- CN202411325471.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Diabetic wounds are abnormally inflammatory responses due to high sugar and high ROS environments, resulting in delayed wound healing and scar formation. The prior art is difficult to effectively inhibit scar production caused by excessive VEGF.
Using a hydrogel based on dynamic borate bonds, a hydrogel that can disconnect the borate bonds and release drugs in an acidic, high sugar and high ROS environment by oxidizing the combination of sodium alginate, benzeneboric acid and arbutin. , promotes the polarization of M1 macrophages to M2, reduces the expression of inflammatory factors, and inhibits collagen deposition and scar formation.
Significantly promotes diabetic wound healing, clears ROS, regulates the inflammatory microenvironment, reduces scar formation, and inhibits pigmentation during wound healing, improving healing speed and quality.
Smart Images

Figure CN118949118A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of hydrogel preparation, and in particular to a hydrogel for repairing non-pigmented scars on diabetic wounds, and a preparation method and application thereof. Background Art
[0002] Diabetes is a common chronic disease. The difficulty in healing of diabetic wounds is not caused by a single factor, but by the accumulation of different factors. In the wound microenvironment of diabetic wounds, the inflammatory response is in an abnormal state for a long time. The inflammatory response is the response of the organism to the invasion of external microorganisms or tissue damage. It plays an important role in clearing microorganisms, self-necrotic cells and tissues, and various cytokines released in the inflammatory response can also participate in the subsequent repair process. In the wound environment of diabetic wounds, macrophages in wound microenvironments such as high sugar and easy bacterial colonization are more likely to differentiate into pro-inflammatory M1 macrophages. The number of such inflammatory cells in the wound increases and the residence time increases. The large presence of inflammatory cells also leads to an increase in the level of oxidative stress in the wound environment. Studies have shown that the content of oxygen free radicals in inflammatory cells such as neutrophils increases, and a large amount of reactive oxygen species (ROS) is released during the non-enzymatic glycosylation reaction. These continuously produced high levels of ROS will damage the ECM structural units, thereby damaging the function of normal cells and leading to delayed wound healing.
[0003] Wound healing begins with the inflammatory phase and overlaps with the subsequent proliferation and remodeling phases. When the immune system senses a threat of damage to the body, it triggers an inflammatory response. The inflammatory response is an essential process for wound healing. A strong inflammatory response in the early inflammatory phase is beneficial for killing bacteria and preventing wound infection. A weakened inflammatory response in the later stage can initiate tissue regeneration and promote wound healing. Timely subsidence of the inflammatory response during the remodeling phase can reduce the secretion of inflammatory factors and growth factors, prevent the factors from further recruiting inflammatory cells and activating fibroblasts, leading to excessive collagen deposition, and is beneficial for inhibiting scar formation. Macrophages are important inflammatory cells that play an important role in all stages of wound healing. Under different physiological conditions, macrophages can be polarized into pro-inflammatory macrophages (M1) or anti-inflammatory macrophages (M2). Among them, M1 macrophages secrete proinflammatory factors such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor (TNF-α), while M2 macrophages release growth factors such as platelet-derived growth factor (PDGF), transforming growth factor (TGF-β) and vascular endothelial growth factor (VEGF). Macrophages show different polarization states at different stages of healing and achieve different functions. The level of vascularization plays different roles at different stages of wound healing. The rapid generation of new blood vessels during the proliferation period is conducive to the formation of granulation tissue and new epidermis, which can accelerate wound healing, while excessive vascular expression during the remodeling period can impair skin healing and lead to fibrosis. By comparing the healing process of fetal scarless wounds, it was found that high expression of VEGF and excessive vascularization can easily lead to scar formation. Neutralizing excessive VEGF can significantly reduce the formation of blood vessels in the wound and effectively inhibit the formation of scars in the wound.
[0004] Therefore, it is crucial to provide new drugs that can neutralize excessive VEGF and effectively inhibit the formation of scars on the wound surface. Summary of the invention
[0005] The purpose of the present invention is to provide a hydrogel for repairing non-pigmented scars on diabetic wounds and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art.
[0006] To achieve the above object, the present invention provides the following solutions:
[0007] One of the technical solutions of the present invention is a method for preparing a hydrogel for repairing non-pigmented scars on diabetic wounds, comprising the following steps:
[0008] (1) mixing oxidized sodium alginate, phenylboric acid and 1-ethyl-(3-dimethylaminopropyl)carbodiimide to obtain modified sodium alginate;
[0009] (2) Methacrylylated gelatin and the modified sodium alginate are dissolved in a buffer solution, arbutin is added, and LAP is used as an initiator to carry out a cross-linking reaction to obtain the hydrogel.
[0010] The second technical solution of the present invention is the hydrogel prepared by the preparation method.
[0011] The third technical solution of the present invention is the use of the hydrogel in the preparation of products for promoting diabetic wound healing.
[0012] A fourth technical solution of the present invention is a product for promoting diabetic wound healing, wherein the product comprises the hydrogel.
[0013] Based on the above technical solution, the present invention has the following technical effects:
[0014] The present invention provides a hydrogel dressing based on a dynamic boronate bond, which can respond to the microenvironment of pH changes, high sugar, and high ROS expression at the diabetic wound. In this microenvironment, the boronate bond will break, thereby releasing the drug, and at the same time combine with glucose to form a new boronate bond, reducing the local glucose concentration. The GAP@AR hydrogel prepared by the present invention has significant antioxidant capacity, can effectively remove excess ROS in diabetic wounds, and can also promote the polarization of pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages, reduce the expression of pro-inflammatory factors, regulate the inflammatory microenvironment, promote wound healing, and at the same time avoid the factors from further recruiting inflammatory cells and activating fibroblasts, resulting in excessive collagen deposition and inhibiting the formation of hypertrophic scars. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0016] Figure 1 is the UV absorbance of arbutin corresponding to GAP@AR under different pH, high ROS and high sugar environments, where A is the UV absorption of arbutin sustained release under different environments and time, and B is the sustained release rate of arbutin under different environments.
[0017] Figure 2 Figure 1 is the antioxidant effect of GAP@AR hydrogel. Figure A shows the UV-visible spectrum curve of GAP@AR hydrogel after 5 minutes of co-incubation with DPPH; Figure B is the DPPH scavenging rate of GAP@AR hydrogel; Figure C is the UV-visible spectrum curve of GAP@AR hydrogel at different times; Figure D is the DPPH dynamic scavenging rate of GAP@AR5% hydrogel; Figure E is the relative fluorescence image of the ROS detection kit for L929 cells scavenging reactive oxygen after being treated with different GAP@AR hydrogels; Figure F is the corresponding relative fluorescence intensity quantification diagram.
[0018] Figure 3 The anti-inflammatory effect of GAP@AR hydrogel. Figure AE is the quantitative expression of different pro-inflammatory factors after inflammatory cells were treated with different GAP@AR hydrogels, A is TNF-α, B is IL-6, C is IL-1β, D is MCP-1, E is IFN-γ, and F is the quantitative release of NO.
[0019] Figure 4 Flow cytometry graph verifying the degree of polarization of inflammatory cells after inflammatory cells were treated with GAP@AR hydrogel.
[0020] Figure 5 These are the results of wound repair in animal experiments, where A is a representative optical image of the diabetic wound in different treatment groups; and B is a contour map of wound closure. DETAILED DESCRIPTION
[0021] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0022] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0023] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0024] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.
[0025] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0026] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.
[0027] The embodiment of the present invention provides a method for preparing a hydrogel for repairing non-pigmented scars on diabetic wounds, comprising the following steps:
[0028] (1) mixing oxidized sodium alginate, phenylboric acid and 1-ethyl-(3-dimethylaminopropyl)carbodiimide to obtain modified sodium alginate;
[0029] (2) Methacrylylated gelatin and the modified sodium alginate are dissolved in a buffer solution, arbutin is added, and LAP is used as an initiator to carry out a cross-linking reaction to obtain the hydrogel.
[0030] In some specific embodiments, the preparation method of oxidized sodium alginate comprises the following steps: sodium alginate is dissolved in ethanol, and NaIO4 solution is added to carry out oxidation reaction to obtain the oxidized sodium alginate; the oxidation reaction is carried out in a dark environment for 2 to 24 hours.
[0031] In some specific embodiments, the oxidation reaction further comprises a step of adding ethylene glycol to terminate the reaction.
[0032] In some specific embodiments, the molar ratio of the oxidized sodium alginate, phenylboric acid and 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 1:2:3.
[0033] In some specific embodiments, the mixing reaction time is 12 to 48 hours.
[0034] In some specific embodiments, the modified sodium alginate is modified sodium alginate with phenylboronic acid groups, and the pH value is 7-9.
[0035] In some specific embodiments, the mass ratio of the methacrylated gelatin to the modified sodium alginate is 10:3.
[0036] In some specific embodiments, the buffer solution is a PBS buffer solution; after adding the methacrylated gelatin and the modified sodium alginate into the PBS buffer solution, they are completely dissolved by ultrasonication at 37° C. for 0.5 to 4 h.
[0037] In some specific embodiments, the mass concentration of arbutin in the hydrogel is 1% to 5%.
[0038] In some specific embodiments, the reaction conditions of the cross-linking reaction are: reacting under 405 nm blue light for 1 to 20 min.
[0039] In some specific embodiments, the gel is successfully formed when there is no obvious color separation after the cross-linking reaction is completed.
[0040] The embodiment of the present invention also provides a hydrogel prepared by the preparation method.
[0041] The embodiment of the present invention also provides the use of the hydrogel in preparing a product for promoting diabetic wound healing.
[0042] An embodiment of the present invention further provides a product for promoting diabetic wound healing, wherein the product comprises the hydrogel.
[0043] Arbutin is a plant polyphenol with excellent antioxidant, anti-inflammatory and tyrosinase inhibitory biological activities. It can effectively remove reactive oxygen species on diabetic wounds and regulate the inflammatory microenvironment, thereby reducing the secretion of inflammatory factors and growth factors, reducing excessive collagen deposition, and inhibiting the formation of hypertrophic scars. Its excellent enzyme inhibition activity can reduce melanin production and also has a good inhibitory effect on pigment scars during wound healing.
[0044] Example 1
[0045] 10g sodium alginate was dissolved in 98% anhydrous ethanol (50mL) by volume, and 2.5g, 5% (w / v) NaIO4 solution was slowly added in a dark environment. After 6h of reaction at room temperature, 15mL of ethylene glycol was added to terminate the reaction to obtain oxidized sodium alginate. 1-ethyl-(3-dimethylaminopropyl)carbodiimide (0.86g, 4.5mmol) was added to the oxidized sodium alginate aqueous solution (0.3g, 1% w / v) and stirred until completely dissolved. 0.41g (3mmol) phenylboric acid was dissolved in 98% anhydrous ethanol (30mL), and added dropwise to the reaction at a molar ratio of 1:2:3. After 24 hours of reaction, a modified sodium alginate with a phenylboric acid group at pH=7 was obtained.
[0046] 100 mg of methacryloyl gelatin (GelMA) and 30 mg of modified sodium alginate with phenylboronic acid groups (ADA-PBA) were dissolved in 1 mL of PBS buffer solution, and the hydrogel precursor solution was completely dissolved by ultrasonication at 20 kHz for 0.5-4 h at 37 ° C. Then, arbutin with different mass fractions (0%, 1%, 3%, and 5%) was added. Phenyl (2,4,6-trimethylbenzoyl) lithium phosphate (LAP) was used as an initiator, and the gel was successfully formed by photocrosslinking under blue light (405 nm) for 5 minutes without obvious color stratification. The gels were named GAP, GAP@AR1%, GAP@AR3%, and GAP@AR5%.
[0047] Example 2
[0048] 1500μL hydrogel GAP@AR5% was added to PBS solutions with pH values of 7.8 and 6.0, H2O2 concentration of 0.3mmol / L and glucose concentration of 16mmol / L to simulate the release of drugs in the hydrogel before and after diabetic wound healing. The samples were incubated at room temperature for different time periods (1d, 3d, 5d, 7d), and the extracts were taken at fixed time points. The spectral changes of different extracts and the corresponding sustained release rates of arbutin drugs were tested by UV spectroscopy.
[0049] The results are as follows Figure 1 As shown, the drug can be better sustained-released in the acidic pH, high ROS and high sugar environment of diabetic wounds.
[0050] 2 Mouse fibroblasts (L929) were inoculated into 6-well plates and incubated at 37°C for 24h. The extracts obtained by soaking the hydrogels GAP@AR1%, GAP@AR3%, and GAP@AR5% in a weak acid environment for 24h were sterilized with a 0.2μm microporous filter and then diluted 10 times with sterile PBS buffer (pH=7.4). The hydrogel extracts were treated with 10-fold diluted Rosup reagent at 1μg / mL and incubated for 6 hours. After washing with sterile PBS buffer (pH=7.4), 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) solution was added and incubated for 20min. The cells on the 24-well plate were then observed and photographed using an inverted fluorescence microscope.
[0051] like Figure 2 As shown in the figure, the DCFH fluorescence intensity of the GAP@AR hydrogel group was significantly lower than that of the Rosup group. These experimental results confirm that the GAP@AR hydrogel has significant antioxidant capacity, can effectively remove excess ROS in diabetic wounds, and promote wound healing.
[0052] 3 1×10 6Mouse mononuclear macrophage leukemia cells (RAW 264.7 cells) were co-cultured with the extracts obtained by soaking GAP@AR1%, GAP@AR3%, and GAP@AR5% in a weak acid environment for 24 hours, and LPS (1μg / ml) was added to the culture medium for 48 hours to induce a systemic inflammatory microenvironment. Subsequently, the levels of pro-inflammatory factors were detected using an enzyme-linked immunosorbent assay (ELISA) kit.
[0053] The results are as follows Figure 3 As shown, GAP@AR hydrogel can reduce the expression of pro-inflammatory factors, regulate the inflammatory microenvironment, and promote wound healing, while preventing the factors from further recruiting inflammatory cells and activating fibroblasts, leading to excessive collagen deposition and inhibiting the formation of hypertrophic scars.
[0054] 4 will 1×10 6 Mouse mononuclear macrophage leukemia cells (RAW 264.7 cells) were co-cultured with the extracts (30 μL) obtained by soaking GAP@AR1%, GAP@AR3%, and GAP@AR5% in a weak acid environment for 24 hours, and 100 ng / ml LPS was added to the culture medium to culture it in a systemic inflammatory microenvironment for 24 hours. In flow cytometry, APC anti-mouse CD86 antibody (Elabscience, E-AB-F0994E), APC anti-mouse CD206 antibody (Elabscience, E-AB-F1135E), and APC anti-mouse F4 / 80 antibody (Elabscience, E-AB-F0995UE) were used to quantify M1 and M2 polarized macrophages by flow cytometry.
[0055] The results are as follows Figure 4 As shown, in the GAP hydrogel group, with the increase of drug, the expression of pro-inflammatory M1 macrophages (CD86 marker) decreased, and the expression of anti-inflammatory M2 macrophages (CD206 marker) increased. The results confirmed that GAP@AR hydrogel has the ability to promote the polarization of macrophages M1 to M2, and plays a role in inhibiting inflammation and repairing tissues.
[0056] 5 Animal experiments used a mouse model of diabetic full-thickness skin defect. C57BL / 6 mice were randomly divided into a blank control group, a 3M group, a GAP group, and a GAP@AR3% group. All animals were anesthetized with 4% chloral hydrate intraperitoneal injection, and then the back hair was shaved with a razor and the hair was removed with a depilatory cream to fully expose the surgical site. Then, a full-thickness wound (8 mm in diameter) was made on the back of each mouse with surgical scissors. Then, the hydrogel (200 μL) or 3M film was applied to the wound, and sterile PBS (50 μL, pH = 7.4) was used as the control group. It was replaced every 3 to 5 days according to the condition of the wound. Wound photos were taken on days 0, 3, 7, 14, and 21, and the wound healing process was closely monitored.
[0057] The results are as follows Figure 5 As shown, the wound area of all groups decreased to some extent over time. However, the wounds of the GAP group and the GAP@AR3% group healed faster after 7 days compared with the control group and the 3m group. After 14 days of healing, the wound healing of the GAP@AR3% group was significantly better than that of the other groups. On day 21, it was observed that the wounds of the GAP@AR3% group were completely healed without pigmentation and scar formation.
[0058] In summary, the present invention uses methacrylated gelatin and oxidized sodium alginate grafted with phenylboronic acid as a matrix and arbutin as a therapeutic agent to prepare a pH, ROS and high sugar multi-responsive hydrogel dressing for scar-free repair of diabetic wounds. Oxidized sodium alginate is combined with phenylboronic acid to generate a modified sodium alginate containing an aldehyde group and a dihydroxyborylphenyl group. When the drug molecule arbutin is added under weakly alkaline conditions, the ortho-dihydroxyl groups of phenylboronic acid and arbutin will form a boron ester bond. Subsequently, the modified sodium alginate with boric acid can form a Schiff base bond with the amino group in the methacrylated gelatin to form a dynamic covalent bond. At the same time, in the presence of a photoinitiator, the vinyl group in the methacrylated gelatin can form a carbon-carbon covalent bond under 405nm ultraviolet light, forming a stable hydrogel network structure with good mechanical properties (elasticity).
[0059] It has been proven that the boron ester bond will break in an acidic, high-sugar and high-ROS environment, thereby releasing the drug, and at the same time, it will combine with glucose to form a new boron ester bond, reducing the local glucose concentration, thereby promoting the healing of diabetic wounds. Arbutin can quickly penetrate into the skin, and while not affecting the cell proliferation concentration, it can effectively inhibit the activity of tyrosinase in the skin and block the formation of melanin. By directly combining with tyrosinase, it accelerates the decomposition and excretion of melanin, thereby reducing skin pigmentation and having a good inhibitory effect on pigment scars during wound healing. At the same time, arbutin's powerful anti-inflammatory and antioxidant effects can reduce the secretion of inflammatory factors and growth factors, preventing the factors from further recruiting inflammatory cells and activating fibroblasts, leading to excessive collagen deposition, which is beneficial to inhibiting scar formation.
[0060] Obviously, the above embodiments of the present invention are merely examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A method for preparing a hydrogel for repairing non-pigmented scars on diabetic wounds, characterized in that: The following steps are involved: (1) mixing oxidized sodium alginate, phenylboric acid and 1-ethyl-(3-dimethylaminopropyl)carbodiimide to obtain modified sodium alginate; (2) Methacrylylated gelatin and the modified sodium alginate are dissolved in a buffer solution, arbutin is added, and LAP is used as an initiator to carry out a cross-linking reaction to obtain the hydrogel.
2. The preparation method according to claim 1, characterized in that: The preparation method of the oxidized sodium alginate comprises the following steps: sodium alginate is dissolved in ethanol, and NaIO4 solution is added to carry out oxidation reaction to obtain the oxidized sodium alginate; the oxidation reaction is carried out in a dark environment for 2 to 24 hours.
3. The preparation method according to claim 1, characterized in that: The molar ratio of the oxidized sodium alginate, phenylboric acid and 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 1:2:
3.
4. The preparation method according to claim 1, characterized in that: The mixing reaction time is 12 to 48 hours.
5. The preparation method according to claim 1, characterized in that: The mass ratio of the methacrylated gelatin to the modified sodium alginate is 10:
3.
6. The preparation method according to claim 1, characterized in that: The mass concentration of the arbutin in the hydrogel is 1% to 5%.
7. The preparation method according to claim 1, characterized in that: The reaction conditions of the cross-linking reaction are: reacting under 405 nm blue light for 1 to 20 minutes.
8. The hydrogel prepared by the preparation method according to any one of claims 1 to 7.
9. Use of the hydrogel as claimed in claim 8 in preparing a product for promoting diabetic wound healing.
10. A product for promoting diabetic wound healing, characterized in that: The product comprises the hydrogel according to claim 8.
Citation Information
Patent Citations
Sol system used for preparing pH-sensitive double-network hydrogel, hydrogel and application
CN110075348A
Multifunctional antibacterial dressing, preparation method and application
CN113499473A
Tissue-adhesive hydrogel and application thereof
CN113941025A
Visible light curing biological tissue binding material based on natural polymer as well as preparation method and application of visible light curing biological tissue binding material
CN114392387A
Glycidyl methacrylate modified gelatin and oxidized sodium alginate double-network hydrogel as well as preparation method and application thereof
CN115216029A
